Premium
The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid‐Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low‐Density Lipoprotein
Author(s) -
Kim TaeEun,
Shin Dongseong,
Gu Namyi,
Jung Byung Hwa,
Kim Jayoun,
Cho Young Min,
Yu KyungSang,
Cho JooYoun
Publication year - 2017
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/bcpt.12826
Subject(s) - rosuvastatin , slco1b1 , single nucleotide polymorphism , chemistry , genotyping , medicine , genotype , endocrinology , polymorphism (computer science) , pharmacology , biochemistry , gene
Rosuvastatin is an HMG ‐CoA reductase inhibitor widely used for treating hypercholesterolaemia. We investigated whether genetic polymorphisms in solute carrier organic anion transporter 2B1 ( SLCO 2B1 ) affect the lipid‐lowering effect of rosuvastatin in healthy adults with elevated low‐density lipoprotein ( LDL ). This study included 18 volunteers with LDL levels above 130 mg/dL. Rosuvastatin (20 mg) was administered once a day for 8 weeks. Blood samples were drawn before and after the 8‐week treatment to measure changes in lipid levels. The presence of single nucleotide polymorphisms ( SNP s) of SLCO 2B1 (c.935G>A and c.1457C>T), SLCO 1B1 (c.521C>T, c.388A>G and c.‐11187G>A) and ABCG 2 (c.421C>A) was determined by genotyping. Responses to rosuvastatin were compared between wild‐type and variant genotypes using permutation test on each polymorphism. In volunteers with SLCO 2B1 c.935G>A (rs12422149) variant, rosuvastatin was less effective at lowering LDL (mean % decrease: GG 62.8% GA 50.6% AA 49.3%, p = 0.012) and apoprotein B (mean % decrease: GG 52.1% GA 42.8% AA 42.8%, p = 0.036). Regarding SLCO 2B1 c.1457C>T (rs2306168) SNP , there was no significant difference between wild‐type and variant genotypes. This study demonstrated that SLCO 2B1 c.935G>A (rs12422149) polymorphism influenced the lipid‐lowering effects of rosuvastatin in volunteers with hypercholesterolaemia.